HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michihiro Yoshimura Selected Research

Thioredoxins

7/2007Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure.
11/2005Increased plasma levels of thioredoxin in patients with glucose intolerance.
3/2005Plasma thioredoxin levels in patients with unstable angina.
2/2004Increased plasma levels of thioredoxin in patients with coronary spastic angina.
1/2004Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
12/2003Increased plasma thioredoxin in patients with acute myocardial infarction.
9/2003Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michihiro Yoshimura Research Topics

Disease

40Heart Failure
01/2023 - 05/2002
33Atrial Fibrillation
11/2023 - 08/2008
25Myocardial Infarction
10/2023 - 06/2002
23Cardiovascular Diseases (Cardiovascular Disease)
10/2023 - 07/2002
18Spasm (Spasms)
01/2016 - 01/2002
14Acute Coronary Syndrome
10/2023 - 09/2006
14Insulin Resistance
09/2023 - 12/2011
14Coronary Artery Disease (Coronary Atherosclerosis)
01/2020 - 09/2003
14Hypertension (High Blood Pressure)
01/2015 - 05/2002
13Inflammation (Inflammations)
12/2018 - 01/2005
11Pathologic Constriction (Stenosis)
01/2022 - 02/2004
11Atherosclerosis
02/2015 - 01/2003
10Heart Diseases (Heart Disease)
09/2023 - 07/2009
10Diabetes Mellitus
07/2018 - 05/2004
9Thrombosis (Thrombus)
10/2023 - 03/2004
8Fibrosis (Cirrhosis)
09/2023 - 02/2003
8Tachycardia (Tachyarrhythmias)
01/2022 - 05/2009
8Left Ventricular Dysfunction
01/2021 - 05/2002
8Muscle Spasticity (Spastic)
01/2020 - 09/2003
8Myocardial Ischemia (Ischemic Heart Diseases)
01/2017 - 04/2004
8Chest Pain (Chest Pains)
07/2007 - 09/2003
7Obesity
09/2023 - 10/2013
7Ischemia
03/2021 - 04/2012
7Cardiomegaly (Heart Hypertrophy)
11/2016 - 02/2003
6Reperfusion Injury
07/2022 - 07/2002
6Type 2 Diabetes Mellitus (MODY)
01/2019 - 05/2005
6Infarction (Infarctions)
01/2019 - 10/2003
6Coronary Stenosis (Coronary Artery Stenosis)
07/2018 - 11/2003
5Essential Hypertension
11/2016 - 05/2002
5Hypertrophy
06/2014 - 03/2006
4Pulmonary Hypertension
02/2024 - 06/2018
4Hypoxia (Hypoxemia)
01/2023 - 05/2005
4Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2022 - 09/2006
4ST Elevation Myocardial Infarction
01/2016 - 01/2011
4Coronary Vasospasm (Coronary Artery Vasospasm)
05/2010 - 01/2002
3Fabry Disease (Fabry's Disease)
06/2022 - 01/2018
3Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy)
06/2022 - 05/2002
3Bradycardia
01/2022 - 05/2009
3Arteriosclerosis
01/2021 - 10/2012
3Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/2020 - 01/2010
3Hypercholesterolemia
01/2018 - 03/2009
3Flushing
12/2016 - 05/2015
3Glucose Intolerance
11/2007 - 01/2005

Drug/Important Bio-Agent (IBA)

27Brain Natriuretic Peptide (Natrecor)FDA Link
10/2023 - 05/2002
16AldosteroneIBA
01/2015 - 05/2002
13Glucose (Dextrose)FDA LinkGeneric
01/2023 - 11/2005
11Natriuretic PeptidesIBA
10/2023 - 05/2002
11Uric Acid (Urate)IBA
09/2023 - 01/2010
11Acetylcholine (Acetylcholine Chloride)FDA Link
01/2020 - 11/2003
8Angiotensin Receptor AntagonistsIBA
01/2023 - 09/2003
8LipidsIBA
01/2022 - 01/2006
8C-Reactive ProteinIBA
12/2018 - 04/2004
7Biomarkers (Surrogate Marker)IBA
01/2021 - 07/2006
7Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 06/2004
7AdiponectinIBA
05/2013 - 05/2004
7ThioredoxinsIBA
07/2007 - 09/2003
6NitratesIBA
03/2021 - 09/2003
6HDL CholesterolIBA
12/2016 - 05/2004
6Antihypertensive Agents (Antihypertensives)IBA
01/2016 - 01/2010
5Oxygen (Dioxygen)IBA
02/2024 - 05/2013
5Insulin (Novolin)FDA Link
01/2023 - 01/2017
5oxidized low density lipoproteinIBA
01/2021 - 03/2009
5Adenosine Triphosphate (ATP)IBA
01/2021 - 10/2011
5Sirolimus (Rapamycin)FDA Link
07/2018 - 01/2011
5CreatinineIBA
03/2016 - 07/2002
5Calcium Channel Blockers (Blockers, Calcium Channel)IBA
10/2014 - 08/2007
4omega-Chloroacetophenone (Mace)IBA
10/2023 - 09/2007
4Atrial Natriuretic Factor (ANF)IBA
07/2022 - 07/2007
4Aldehyde DehydrogenaseIBA
01/2020 - 05/2015
4Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2020 - 02/2014
4Adenosine (Adenocard)FDA LinkGeneric
11/2016 - 08/2010
4SodiumIBA
06/2014 - 03/2006
4Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
11/2007 - 01/2003
4Plasminogen InactivatorsIBA
05/2004 - 01/2003
3Adrenocorticotropic Hormone (ACTH)FDA Link
10/2023 - 02/2005
3Malondialdehyde (Propanedial)IBA
01/2021 - 01/2015
3LDL Lipoproteins (beta Lipoproteins)IBA
01/2021 - 01/2015
3GadoliniumIBA
12/2020 - 11/2011
3Indicators and Reagents (Reagents)IBA
01/2018 - 03/2006
3Eicosapentaenoic AcidIBA
01/2018 - 01/2016
3Arachidonic Acid (Vitamin F)IBA
01/2018 - 01/2016
3PotassiumIBA
01/2017 - 01/2010
3Creatine Kinase (Creatine Phosphokinase)IBA
01/2015 - 01/2013
3Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
01/2015 - 03/2006
3Pioglitazone (Actos)FDA Link
12/2014 - 05/2013
3Hydrocortisone (Cortisol)FDA LinkGeneric
10/2014 - 02/2005
3Proteins (Proteins, Gene)FDA Link
06/2014 - 07/2009
3Oxidants (Oxidizing Agents)IBA
05/2013 - 02/2003
3Lipoproteins (Lipoprotein)IBA
03/2009 - 06/2004
3AntioxidantsIBA
07/2007 - 01/2004
3CholesterolIBA
04/2006 - 05/2004
3Cytochrome P-450 CYP11B2 (CYP11B2)IBA
01/2005 - 08/2002

Therapy/Procedure

28Therapeutics
06/2022 - 07/2002
27Catheter Ablation
11/2023 - 08/2008
11Stents
10/2023 - 07/2005
7Catheters
01/2023 - 05/2002
6Aftercare (After-Treatment)
11/2019 - 03/2005
5Radiofrequency Ablation
01/2022 - 11/2016
4Percutaneous Coronary Intervention
01/2021 - 06/2004
4Drug-Eluting Stents
07/2015 - 10/2009